George Perry to Cholinesterase Inhibitors
This is a "connection" page, showing publications George Perry has written about Cholinesterase Inhibitors.
Connection Strength
0.275
-
Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015; 44(2):549-60.
Score: 0.124
-
Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G. Therapeutic options in Alzheimer's disease. Expert Rev Neurother. 2006 Jun; 6(6):897-910.
Score: 0.068
-
Kalaria RN, Kroon SN, Grahovac I, Perry G. Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease. Neuroscience. 1992 Nov; 51(1):177-84.
Score: 0.027
-
Mondrag?n-Rodr?guez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ, Smith MA. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother. 2010 May; 10(5):683-91.
Score: 0.022
-
Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2008 Apr-May; 62(4):199-207.
Score: 0.019
-
Marlatt MW, Webber KM, Moreira PI, Lee HG, Casadesus G, Honda K, Zhu X, Perry G, Smith MA. Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem. 2005; 12(10):1137-47.
Score: 0.015